Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer

Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer

Immunotherapy on its own is better than aggressive chemotherapy as a first-line treatment for advanced head and neck cancer, according to surprising new data from a major phase III clinical trial.

Patients lived for longer and had far lower rates of side-effects if they took the immunotherapy drug pembrolizumab than those who received an ‘extreme’ combination of two chemotherapies and a targeted drug.

People with an immune hallmark called PD-L1 in their tumours did particularly well on pembrolizumab – living for around 40 per cent longer.

And while only around a fifth of patients overall responded to pembrolizumab, those who did so often did spectacularly well – with a median length of response of 20.9 months compared with only 4.2 months with aggressive chemotherapy.

The trial was led in the UK by a team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, and involved 206 research centres worldwide.

Its findings could in future see immunotherapy become a standard, first-line treatment for advanced head and neck cancer, and spare many patients the side-effects associated with combination chemotherapy.

The study is being presented at the European Society for Medical Oncology (ESMO) Congress 2018 in Munich today (Monday), and was sponsored by Merck & Co., Inc.

Patients would normally be given aggressive chemotherapy if diagnosed at an advanced stage when the cancer has begun to spread to try to get rid of all the cancer cells as quickly as possible.

But the new trial sought to see if immunotherapy, in combination with chemotherapy or on its own, could be a more effective and kinder option.

The researchers randomly assigned 882 patients in equal numbers to one of three treatment groups – receiving the ‘extreme’ chemotherapy combination, and the immunotherapy pembrolizumab with platinum chemotherapy or on its own.

Patients with high levels of the immune marker PD-L1 in their tumours received the biggest benefit from pembrolizumab – living for a median of 14.9 months after diagnosis compared with 10.7 months with the aggressive combination.

But patients with lower levels of PD-L1 also saw benefit, living 12.3 months taking pembrolizumab compared with 10.3 for those who received the combination.

Importantly, only 17 per cent of patient experienced serious side-effects with pembrolizumab, compared with 69 per cent of those taking the ‘extreme’ therapy.

The only downside to pembrolizumab on its own was that fewer people in total responded. Even in the group with high levels of PD-L1, 23 per cent of patients who received the treatment responded, compared with 36 per cent for chemotherapy.

The response rate was higher, at 36 per cent, for patients who received platinum chemotherapy alongside pembrolizumab – but these patients had the same high rate of side-effects as those on the aggressive chemotherapy combination.

Pembrolizumab is an immune checkpoint inhibitor that targets PD-L1 on the surface of cancer cells. Blocking PD-L1 in this way takes the ‘brakes’ off the immune system, setting it free to attack cancer cells.

The findings are consistent with previous studies of checkpoint inhibitor immunotherapies and illustrate the pros and cons of these drugs – their excellent responses in some patients, but the fact that only a minority of patients respond.

Professor Kevin Harrington, Professor of Biological Cancer Therapies at The Institute of Cancer research, London and Consultant Clinical Oncologist at The Royal Marsden Foundation Trust, said:

“Our study has shown that the immunotherapy pembrolizumab on its own is better than an aggressive triple-whammy of two types of chemotherapy plus a targeted drug as first-line treatment for advanced head and neck cancer.

“We couldn’t believe it when we saw the results. None of us expected pembrolizumab on its own to work so well in some of these patients – and it raises the prospect that we could spare some people chemotherapy altogether.

“The study could have major implications for the treatment of advanced head and neck cancers – taking immunotherapy from a last resort to the treatment we turn to first for some patients. The trial is still ongoing, but we expect some patients to go on to live for years longer than they would have done had they received standard chemotherapy.”

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:

“We’re used to seeing immunotherapy trialled in patients who have exhausted other options – but this trial has shown its true potential as a smarter, kinder and more effective first-line treatment for cancer, where it can have the biggest impact on a patient’s life.

“This trial showed the benefits of immunotherapy in head and neck cancer, but I’m optimistic that the same will hold true for other cancers. We now need to do two things to ensure more patients can benefit from immunotherapy – develop ways of getting these drugs to work in a higher proportion of patients, and come to an agreement over the cost of these drugs to make them more affordable for the NHS.”

Source:

https://www.icr.ac.uk/news-archive/esmo-2018-immunotherapy-effective-as-first-line-treatment-for-advanced-head-and-neck-cancer

About author

Related Articles